Synopsis:
Senores Prescription drugs jumped sharply after its internet revenue grew 131% YoY to Rs 30.1 crore on account of strong progress in its regulated markets and elevated effectivity. Attributable to sturdy worldwide demand for its advanced generics, income elevated 56% to Rs 153 crore, and margins improved considerably.
The shares of this main producer and developer of inexpensive and high-quality advanced generics are in focus after reporting stellar Q2 outcomes. On this article, we are going to dive extra into the main points of it.
With a market capitalisation of Rs 3,685 crore, the shares of Senores Prescription drugs Ltd made a day excessive of Rs 829.55 per share, up by 8 % from its earlier day closing worth of Rs 766.80 per share. Publish its itemizing on the inventory exchanges in December 2024, the inventory has delivered a optimistic return of 40 %.
Q2 Highlights
Senores has reported a income from operations of Rs 153.4 crore in Q2 FY26, representing a 56 % progress in comparison with Rs 98.3 crore in Q2 FY25. Moreover, on a quarter-on-quarter foundation, it grew by 18 % from Rs 130.3 crore. One key spotlight is that its gross margins elevated by a staggering 1,230 bps through the quarter.
The corporate’s working efficiency was wonderful in Q2 FY26 as its EBITDA (excluding different earnings) elevated to Rs 49.5 crore (113 % progress) as in comparison with Rs 23.3 crore in the identical quarter final 12 months. Consequently, its EBITDA margin has considerably gone up by 750 bps to 30.6 % from 23.1 %, reflecting improved value management and better effectivity.
Relating to its profitability, it reported a internet revenue of Rs 30.1 crore in Q2 FY26, a staggering progress of 131 % as in comparison with Rs 13.1 crore in Q2 FY25. Moreover, on a quarter-on-quarter foundation, it grew by 42 % from Rs 21 crore. PAT margins additionally improved by 560 bps to 18.6 % in Q2 FY26.
The corporate’s Regulated Markets phase carried out nicely in Q2 FY26, with income rising 87 % YoY to Rs 107 crore, primarily due to elevated exports and product approvals. Nonetheless, due to weaker demand in some areas, the Rising Markets phase noticed a 13 % decline to Rs 32 crore. With a exceptional 1,337 % enhance to Rs 12 crore, the Branded Generics firm confirmed a dramatic turnaround from a low place to begin. Attributable to pricing pressures and decreased offtake, the API phase noticed a 20.5 % YoY decline to Rs 3 crore.
To be exact, as of Q2 FY26, it derives 66.1 % of its income from regulated markets, adopted by 19.6 % from rising markets, and the remaining 14.4 % of its complete income is sourced from others.
Senores Prescription drugs is a multinational pharmaceutical firm centered on analysis that creates and produces quite a lot of medicines for markets within the US, Canada, and greater than 40 different nations. Its portfolio consists of 32 contract manufacturing merchandise bought in the USA and 81 permitted merchandise (ANDAs). The corporate, which has almost 400 product registrations worldwide and regulatory approvals in over ten international locations, makes a speciality of advanced generics, crucial care injectables, and APIs.
Senores runs two formulation amenities for rising markets: one in Atlanta, USA, which has USFDA approval, and one other in Chhatral, India, which has WHO-GMP certification. With a view to innovate and broaden its product line for worldwide markets, it additionally operates two API amenities near Ahmedabad and has three R&D facilities: two in India and one within the US.
Written by Satyajeet Mukherjee
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the creator are usually not responsible for any losses precipitated because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
